Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.
Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...
Goldman Sachs raised the firm’s price target on Arrowhead (ARWR) to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the ...
Fintel reports that on November 20, 2025, Goldman Sachs maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with ...
In a report released today, Mayank Mamtani from B. Riley Securities maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $61.00. The company’s shares closed yesterday at $38.03 ...
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback